Skip to main content
LIVN logo

LivaNova PLC (LIVN) Stock: Price, Forecast & Analyst Target

LivaNova PLC (LIVN) — MoonshotScore 88/100 (Exceptional band), calculated Nov 18, 2026. Price $94.54 (+2.85%), as of the Nov 18, 2026 trading session; market cap $5.21B.

Educational signal · not a buy or sell recommendation · How to read this

$94.54 +$2.62 (+2.85%) Market Cap $5.21B

LivaNova PLC · LIVN · NASDAQ

LivaNova PLC is a global medical device company focused on therapeutic solutions across cardiopulmonary, neuromodulation, and advanced circulatory support. The company sells its products through direct sales representatives and independent distributors.

Price as of Nov 18, 2026

Key Statistics

88 of 100

MoonshotScore v2 · LivaNova (LIVN)

Exceptional
Business Quality Elite (86)
Financial Safety Sound (72)
Valuation Full (51)
Growth Durability Compounding (83)
Momentum Surging (93)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, a strong balance sheet and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.

  • EPS beat 8 of the last 8 reports
  • Altman Z 3.17 · Piotroski F 7
  • ROE 15.5% · ROA 5.1% · current ratio 1.46

Helping: business quality, balance-sheet strength, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for LIVN (52 recorded, newest six shown)
RecordedScoreBand
87Exceptional
88Exceptional
88Exceptional
88Exceptional
88Exceptional
88Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$94.54
Change on the day+2.85%
52-week range$52.37 – $99.38
Market capitalisation$5.21B—
Price / earnings (trailing)25.68
Shares traded on the day1.32M

Price & events

Other perspectives

Council score for LivaNova (LIVN): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Moderate
Valuation Neutral
Growth Durability Strong
Momentum Strong

Legends Council

3 lenses, 3 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Moderate
Debt/Equity Moderate
ROE Moderate
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is LivaNova (LIVN), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. LivaNova PLC (LIVN) is listed on NASDAQ. It employs 3,300 people and is led by Vladimir A. Makatsaria. The market values it at $5.21B.

2 · Latest results

What do the latest results show for LivaNova (LIVN)?

Short answer · as of

Against analyst estimates the company has EPS beat 8 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$358M$27M$0.49 (diluted)
Q4 FY2025$361M$31M$0.56 (diluted)
Q1 FY2026$362M$22M$0.40 (diluted)
Q2 FY2026$391M$109M$1.93 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for LivaNova (LIVN)?

Short answer

The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 3.17 · Piotroski F 7. Trailing ratios: ROE 15.5% · ROA 5.1% · current ratio 1.46.

4 · What to check next?

What should you watch next at LivaNova (LIVN)?

Short answer · as of

Current published price targets run low $85.00 · high $120.00 · consensus $100.00 · median $93.00 against a quoted price of $94.54 (as of Nov 18, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does LivaNova compare with its peers?

Short answer

LivaNova's score ranks 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Globus Medical, Inc. (GMED) Same industry, near in market value$70.53 Nov 18, 2026$9.34B94 5-pillar Nov 18, 2026
Penumbra, Inc. (PEN) Same industry, near in market value$320.50 Nov 18, 2026$12.6B92 5-pillar Nov 18, 2026
LivaNova (LIVN) — this page$94.54$5.21B88
UFP Technologies, Inc. (UFPT) Same industry, near in market value$305.65 Nov 18, 2026$2.37B87 5-pillar Nov 18, 2026
Insulet Corporation (PODD) Same industry, near in market value$139.98 Nov 18, 2026$9.71B85 5-pillar Nov 18, 2026
Smith & Nephew plc (SNN) Same industry, near in market value$30.32 Nov 18, 2026$12.7B84 5-pillar Nov 18, 2026
Align Technology, Inc. (ALGN) Same industry, near in market value$163.96 Nov 18, 2026$11.6B83 5-pillar Nov 18, 2026
Bio-Rad Laboratories, Inc. (BIO) Same industry, near in market value$370.17 Nov 18, 2026$9.95B77 5-pillar Nov 18, 2026
Integer Holdings Corporation (ITGR) Same industry, near in market value$126.97 Nov 18, 2026$4.32B68 5-pillar Nov 18, 2026
TransMedics Group, Inc. (TMDX) Same industry, near in market value$96.43 Nov 18, 2026$3.35B68 5-pillar Nov 18, 2026
Bruker Corporation (BRKR) Same industry, near in market value$63.26 Nov 18, 2026$9.66B59 5-pillar Nov 18, 2026
Legend Biotech Corporation (LEGN) Named competitor$16.25 Nov 18, 2026$3.15B38 5-pillar Nov 18, 2026
AxoGen, Inc. (AXGN) Same industry, near in market value$56.95 Nov 18, 2026$3.40B38 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$85.00 – $120.00
Consensus target
$100.00
Median target
$93.00

Consensus record · Captured .

Measured against a quoted price of $94.54 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 15, 2026

Transactions
51
Identified insiders
12
Purchases
0
Sales
6
Other transactions
45

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held LIVN in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported LIVN in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about LivaNova (LIVN)?

Read these with our analysis →

LivaNova Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the LIVN research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for LIVN?

LIVN carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. LivaNova PLC is a global medical device company focused on therapeutic solutions across cardiopulmonary, neuromodulation, and advanced circulatory support.

Is LIVN a good stock to buy?

Stock Expert AI does not rate LIVN buy, sell or hold. LivaNova PLC carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the LIVN stock price today?

The last price recorded for LivaNova PLC (LIVN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the LIVN price target?

The analyst consensus price target for LivaNova PLC (LIVN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for LIVN?

LivaNova PLC faces several risks inherent in the medical device industry. These include product liability claims and litigation related to medical devices, regulatory hurdles and delays in product approvals, intense competition from established medical device companies, and economic downturns affecting healthcare spending.

What are the key factors to evaluate for LIVN?

LivaNova PLC (LIVN) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Adapting its product offerings to meet the specific needs of these markets will be crucial for success. Not financial advice.

How frequently does LIVN data refresh on this page?

LIVN's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven LIVN's recent stock price performance?

LivaNova PLC (LIVN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio across multiple therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider LIVN overvalued or undervalued right now?

The trailing P/E of LivaNova PLC (LIVN) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 10 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.